Ethyl Acetate Fraction of Amomum xanthioides Exerts Antihepatofibrotic Actions via the Regulation of Fibrogenic Cytokines in a Dimethylnitrosamine-Induced Rat Model

الملخص EN

Amomum xanthioides has been traditionally used to treat diverse digestive system disorders in the Asian countries.

We investigated antihepatofibrotic effects of ethyl acetate fraction of Amomum xanthioides (EFAX).

Liver fibrosis is induced by dimethylnitrosamine (DMN) injection (intraperitoneally, 10 mg/kg of DMN for 4 weeks to Sprague-Dawley rats).

EFAX (25 or 50 mg/kg), silymarin (50 mg/kg), or distilled water was orally administered every day.

The DMN injection drastically altered body and organ mass, serum biochemistry, and platelet count, while EFAX treatment significantly attenuated this alteration.

Severe liver fibrosis is determined by trichrome staining and measurement of hydroxyproline contents.

EFAX treatment significantly attenuated these symptoms as well as the increase in oxidative by-products of lipid and protein metabolism in liver tissues.

DMN induced a dramatic activation of hepatic stellate cells and increases in the levels of protein and gene expression of transforming growth factor-beta (TGF-β), platelet derived growth factor-beta (PDGF-β), and connective tissue growth factor (CTGF).

Immunohistochemical analyses revealed increases in the levels of protein and gene expression of α-smooth muscle actin.

These alterations were significantly normalized by EFAX treatment.

Our findings demonstrate the potent antihepatofibrotic properties of EFAX via modulation of fibrogenic cytokines, especially TGF-β in the liver fibrosis rat model.